SARS-CoV-2: Host-pathogen interaction, vaccines & variants of concern
July 8, 2021
- July 8, 2021
- Organized By:
About the Speakers:
Professor Miles W. Carroll
Head of Emerging Pathogens Group
Nuffield Department of Medicine
Head of Research & Development Institute
National Infection Service, Public Health England
Professor Miles Carroll holds joint positions as: Deputy Director, Head of Research & Development Institute, National Infection Service, Public Health England & Principle Investigator in the Nuffield Department of Medicine, Oxford University.
His research portfolio includes: naturally acquired immunity to EBOV & SARS-CoV-2, host pathogen interactions, vaccine development, and the application of molecular epidemiology to high consequence infectious disease outbreaks.
Miles gained his PhD in HIV vaccine research from the University of Manchester and continued his studies on recombinant poxviruses with Dr. Bernie Moss at the National Institutes of Health, USA. On his return to the UK, Miles joined Oxford Biomedica (OBM) as Vice President of Immunotherapy. At OBM Miles invented the therapeutic cancer vaccine candidate, TroVax and led the pre-clinical and Phase II development programme.
Miles has authored >200 publications, has >15 granted patents and serves on several scientific advisory boards including the Animal and Plant Health Agency, Defence Science & Technology Laboratories and the World Health Organisation R&D Road Map for Priority Pathogens.
Professor Julian A. Hiscox
Chair, Infection and Global Health
Deputy Associate Pro-Vice Chancellor Research and Impact (FHLS),
Institute of Infection, Veterinary and Ecological Sciences
University of Liverpool
Professor Julian A. Hiscox is Chair of Infection and Global Health at the University of Liverpool and Deputy Executive Dean of the Institute of Infection, Veterinary and Ecological Sciences. He leads a $6.6M US Food and Drug Administration funded international research program on the ‘Characterization of severe coronavirus infection in humans and model systems for medical countermeasure development and evaluation’. Julian has worked on coronaviruses and the closely related arteriviruses since starting his PhD in 1991. His laboratory specialises in analyses samples from patients with high consequence infections and biological and chemical threat agents. His laboratory deployed to the West African Ebola outbreak as part of the European Mobile Laboratory to aid the country diagnostics and follow virus evolution. He has worked on MERS-coronavirus in Saudi Arabia for the past three years and currently a major focus of his work is on SARS-CoV-2 (the caustive agent of COVID-19). Because of his coronavirus experience he is a co-opted member of the New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG), an expert committee of the Department of Health and Social Care (DHSC), which advises the Chief Medical Officer (CMO). He has a visiting professorship at Northwest A&F University in China and also an adjunct professor at A*STAR in Singapore.
About the Presentation:
Professors Carroll and Hiscox’s studies reveal how the human body responds to severe SARS-CoV-2 infection which will help in future treatments of COVID-19 patients. They will also present results on the immunological response to infection and vaccination, in addition to the potential impact of new variants of the virus that are continuously evolving. This work is supported by FDA’s Medical Countermeasures Initiative (MCMi).
• Discuss using transcriptomics to study the host-pathogen interaction during infection with SARS-CoV-2.
• Describe characterization of the immune response to infection and/or vaccination.
• Explain how viruses evolve and assessing the impact of SARS-CoV-2 variants of concern.
Activity Outline FDA Grand Rounds: July 8, 2021
For technical assistance please contact Niccole.Corbin@fda.hhs.gov.
|Activity Outline FDA Grand Rounds: July 8, 2021||pdf (204.19 KB)|